| etoposide oral / Generic mfg. |
NCT00000807: Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy |
|
|
| Completed | 2 | 41 | US | Etoposide | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb | Sarcoma, Kaposi, HIV Infections | | 07/00 | | |
NCT00002880: Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 53 | US | Etoposide phosphate | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Lymphoma | 01/01 | 01/08 | | |
NCT00003996: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
|
|
| Completed | 2 | 93 | US | carmustine, chemotherapy, cisplatin, etoposide, radiation therapy | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 08/01 | 05/08 | | |
NCT00014313: Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor |
|
|
| Terminated | 2 | 3 | Europe | cisplatin, etoposide | European Organisation for Research and Treatment of Cancer - EORTC | Sarcoma | 12/02 | | | |
NCT00004110: Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma |
|
|
| Completed | 2 | | US | monoclonal antibody 3F8, etoposide, isotretinoin | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Neuroblastoma | 09/04 | | | |
NCT00151060: Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate |
|
|
| Completed | 2 | 28 | US | Estramustine, Etoposide, Paclitaxel | University of Michigan Rogel Cancer Center | Prostate Cancer | 11/04 | 06/06 | | |
NCT00003621: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma |
|
|
| Completed | 2 | 29 | US | carmustine, cisplatin, etoposide, radiation therapy | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 02/05 | 07/05 | | |
NCT00193531: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma |
|
|
| Completed | 2 | 100 | NA | Paclitaxel, Carboplatin, Etoposide | SCRI Development Innovations, LLC, Bristol-Myers Squibb | Neuroendocrine Carcinoma | 01/07 | 01/07 | | |
NCT00003573: Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma |
|
|
| Completed | 2 | 53 | US, Canada, Europe | filgrastim, Granulocyte Colony-Stimulating Factor, r-metHuG-CSF, G-CSF, Neupogen®, NSC #614629, cisplatin, Cis-diamminedichloroplatinum II, CDDP, Platinol, NSC #119875, cyclophosphamide, CTX, Cytoxan, NSC #026271, IND #7089, etoposide, VP-16, VePesid, NSC #141540, IND #9197, vincristine sulfate, VCR, Oncovin, NSC #067574, IND #7161, radiation therapy | Children's Oncology Group, National Cancer Institute (NCI) | Brain Tumors, Central Nervous System Tumors | 10/07 | 03/08 | | |
PEPI, NCT00578864: Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma |
|
|
| Completed | 2 | 13 | US | Protracted Oral Etoposide, Doxorubicin, IV Bolus Etoposide, Cisplatin, Cyclophosphamide, Mesna, Hematopoietic Factor, Primary tumor resection | Baylor College of Medicine | Neuroblastoma | 07/09 | 03/15 | | |
NCT00028769: S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer |
|
|
| Completed | 2 | 41 | US | bicalutamide, estramustine, estramustine phosphate sodium, etoposide, flutamide, goserelin, leuprolide, leuprolide acetate, nilutamide, paclitaxel | Southwest Oncology Group, National Cancer Institute (NCI) | Prostate Cancer | 06/10 | 07/11 | | |
ChiCTR-TNC-09000357: Maintenance treatment with orally etoposide for extensive stage small cell lung cancer: a phase II study |
|
|
| Completed | 2 | 30 | | EP regimen: Etoposide 100mg/m2, day 1-4 + Cisplatin 80mg/m2, day1 or divided to 3 days, repeated every 21 days for 4 cycles. Maintenance therapy: Orally Etoposide 50mg/m2, day1-14, repeated every 21 days till tumor progression is detected. | West China hospital, Sichuan University; Level of the institution：, self-funded | Small cell lung cancer (Extensive stage) | | | | |
NCT00602771: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia |
|
|
| Completed | 2 | 84 | US | tipifarnib, R115777, Zarnestra, etoposide, EPEG, VP-16, VP-16-213 | National Cancer Institute (NCI) | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | 10/11 | 10/11 | | |
| Terminated | 2 | 4 | Canada, US, Europe | Erlotinib, Tarceva, OSI-774 | OSI Pharmaceuticals | Ependymoma | 09/12 | 09/12 | | |
| Terminated | 2 | 25 | Canada, US, Europe | erlotinib, OSI-774, Tarceva, etoposide, VP-16 | OSI Pharmaceuticals | Recurrent or Refractory Pediatric Ependymoma | 11/12 | 11/12 | | |
NCT01492556: Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer |
|
|
| Unknown status | 2 | 100 | RoW | Etoposide, Lastet, VP-16 | Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Beijing Chao Yang Hospital, China-Japan Friendship Hospital, Beijing Hospital of the Ministry of Health, The First Affiliated Hospital of Dalian Medical University, Harbin Medical University, Zhejiang Cancer Hospital, Henan Cancer Hospital, Guangxi Cancer Hospital, Shanghai Putuo District Center Hospital, International Peace Maternity and Child Health Hospital, Xinjiang Medical University | Breast Cancer | 06/14 | 06/15 | | |
AREN0321, NCT00335556: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors |
|
|
| Completed | 2 | 291 | US, Canada, RoW | Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, surgery, conventional, Cyclophosphamide, Etoposide, Lastet, Carboplatin, Dactinomycin, Lyovac Cosmegen, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor | 12/15 | | | |
2006-000570-78: PHASE I/II STUDY OF TEMOZOLOMIDE COMBINED WITH ORAL ETOPOSIDE IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA COHORT A , AND MALIGNANT GLIAL TUMOUR COHORT B |
|
|
| Completed | 2 | 24 | Europe | LASTET FIALE*IV 10F 100MG 5ML, TEMODAL*1FL 5CPS 20MG, LASTET FIALE*IV 10F 100MG 5ML, TEMODAL*1FL 5CPS 20MG | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA AND MALIGNANT GLIAL TUMOUR IN CHILDREN AND YOUNG ADULTS | | | | |
2008-006051-40: A PHASE II STUDY: UNOPERABLE NON NON SQUAMOUS NON SMALL CELL LUNG CANCER METRONOMIC BIOCHEMOTHERAPY WITH WEEKLY CISPLATIN, DAILY ORAL ETOPOSIDE AND BEVACIZUMAB (mPEBev regimen) |
|
|
| Completed | 2 | 28 | Europe | AVASTIN, CISPLATINO TEVA*EV 10MG 20ML, VEPESID, AVASTIN, CISPLATINO TEVA*EV 10MG 20ML, VEPESID | AZIENDA OSPEDALIERA SENESE | Patients with UNOPERABLE NON NON SQUAMOUS NON SMALL CELL LUNG CANCER | | | | |
ChiCTR-IIR-17012870: A prospective and multicenter study of apatinib mesylate combine with etoposide orally to treat platinum-resistant relapse ovarian cancer |
|
|
| Not yet recruiting | 2 | 60 | | Apatinib Mesylate Tablets: 500mg, PO.QD, continuous administration; Etoposide Capsules 100mg, PO.Qd, D1-D10, Q3W. The tolerance of Apatinib Mesylate Tablets is evaluated at 14th day after administration, subjects with well tolerance will increase the dose to 750mg, qd. Untill the disease progress. ;Etoposide Capsules 100mg, PO.Qd, D1-D10, Q3W. Untill the disease progress. | GuangXi Medical University Affiliated Tumor Hospital; GuangXi Medical University Affiliated Tumor Hospital, Self-financing | ovarian cancer | | | | |
NCT03535961: Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer |
|
|
| Completed | 2 | 32 | RoW | apatinib+oral etoposide | Chinese Academy of Medical Sciences | Breast Cancer | 05/19 | 05/19 | | |
NCT03389087: Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer |
|
|
| Unknown status | 2 | 60 | RoW | Apatinib and Etoposide Capsule | Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Small Cell Lung Cancer | 11/19 | 11/21 | | |
ChiCTR1800019970: Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, Controlled, prospective study |
|
|
| Not yet recruiting | 2 | 78 | | Apatinib combined with oral etoposide ;oral etoposide | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | platinum-resistant or platinum-refractory ovarian cancer | | | | |
ChiCTR1800018497: Apatinib combined with oral etoposide in patients as second- or later-line with triple negativebreast cancer: a phase II, single-arm, prospective study |
|
|
| Recruiting | 2 | 40 | | Apatinib combined with oral etoposide | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Triple negativebreast cancer | | | | |
NCT04383977: Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer |
|
|
| Unknown status | 2 | 54 | NA | Apatinib and Etoposide capsule, Apatinib | Jiangsu HengRui Medicine Co., Ltd. | Ovarian Cancer | 12/20 | 06/21 | | |
NCT03901118: Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer |
|
|
| Completed | 2 | 47 | RoW | chiauranib, CS2164, etoposide, Lastet, paclitaxel, Anzatax | Chipscreen Biosciences, Ltd. | Ovarian Cancer | 12/20 | 12/20 | | |
ChiCTR-IIR-16008431: A randomized control study of maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus cisplatin in extensive small-cell lung cancer |
|
|
| Not yet recruiting | 2 | 100 | | maintenance with oral etoposide ;no | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, researcher | lung cancer | | | | |
NCT04217798: Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Niraparib, oral etoposide | Peking Union Medical College Hospital, Zai Lab (Shanghai) Co., Ltd. | Ovarian Cancer | 03/22 | 06/22 | | |
NCT04452370: Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | oral etoposide + anlotinib, there is no other intervention name | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 07/22 | 07/23 | | |
| Completed | 2 | 18 | Europe | metronomic therapy, Dociton, Celebrex, Endoxan, Lastet, Vinblastinsulfat Teva | University of Cologne | Recurrent Neuroblastoma | 06/23 | 06/23 | | |
NCT05685550: Safety and Efficacy of Oral Etoposide Combined With Antirotinib and Envollizumab in Elderly Patients With Lung Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | Toposide capsules combined with anrotinib and Emvolizumab group, Combined treatment group | Tianjin Medical University Cancer Institute and Hospital | Progression Free Survival(PFS) | 12/23 | 05/24 | | |
NCT06463171: Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 60 | RoW | Almonertinib, Lastet | Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Zhongshan Hospital, The First Affiliated Hospital of Xiamen University | Lung Cancer Non-small Cell Stage IV | 06/26 | 06/26 | | |
NCT06436144: Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC |
|
|
| Not yet recruiting | 2 | 93 | NA | Osimertinib, Etoposide Soft Capsules | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | 06/29 | 12/29 | | |
NCT04501718: Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children |
|
|
| Recruiting | 2 | 44 | RoW | Apatinib Combined With Temozolomide and Etoposide Capsules | Beijing Sanbo Brain Hospital | Recurrent Medulloblastoma | 08/24 | 08/24 | | |
NCT04804007: Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT |
|
|
| Recruiting | 2 | 64 | US | Etoposide | Nabil Adra | Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor | 12/27 | 12/28 | | |
TUC-TOC, NCT05955170: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 2 | 66 | Europe | Tucatinib in Combination of Oral VP16 and trastuzumab | Institut Curie, Seagen Inc. | HER2-positive Breast Cancer | 12/26 | 12/27 | | |
NCT01165112: Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma |
|
|
| Completed | 1/2 | 48 | US | Bendamustine Hydrochloride, Ribomustin, SyB L-0501, Treanda, Carboplatin, Rituximab, MOAB IDEC-C2B8, Etoposide, Lastet, Laboratory Biomarker Analysis | University of Washington, National Cancer Institute (NCI) | Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | 06/15 | 06/15 | | |
